BNN Fundamental Analysis - BRAIN BIOTECH AG

Fundamental Rating

BNN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 72 industry peers in the Chemicals industry. BNN may be in some trouble as it scores bad on both profitability and health. BNN does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BNN has reported negative net income.

In the past year BNN has reported a negative cash flow from operations.

In the past 5 years BNN always reported negative net income.

In the past 5 years BNN always reported negative operating cash flow.

1.2 Ratios

BNN's Return On Assets of -17.27% is on the low side compared to the rest of the industry. BNN is outperformed by 86.30% of its industry peers.

With a Return On Equity value of -227.22%, BNN is not doing good in the industry: 93.15% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-17.27%
ROE	-227.22%
ROIC	N/A

ROA(3y)-10.89%

ROA(5y)-10.5%

ROE(3y)-49.48%

ROE(5y)-41.57%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BNN's Gross Margin of 55.60% is amongst the best of the industry. BNN outperforms 84.93% of its industry peers.

BNN's Gross Margin has been stable in the last couple of years.

BNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	55.6%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.53%

GM growth 5Y-0.08%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.

BNN has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for BNN has been increased compared to 5 years ago.

Compared to 1 year ago, BNN has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -0.96, we must say that BNN is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of BNN (-0.96) is worse than 90.41% of its industry peers.

A Debt/Equity ratio of 0.74 indicates that BNN is somewhat dependend on debt financing.

The Debt to Equity ratio of BNN (0.74) is worse than 68.49% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.74
Debt/FCF	N/A
Altman-Z	-0.96

ROIC/WACCN/A

WACC6.6%

2.3 Liquidity

BNN has a Current Ratio of 1.85. This is a normal value and indicates that BNN is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.85, BNN perfoms like the industry average, outperforming 57.53% of the companies in the same industry.

A Quick Ratio of 1.30 indicates that BNN should not have too much problems paying its short term obligations.

The Quick ratio of BNN (1.30) is better than 68.49% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.85
Quick Ratio	1.3

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BNN have decreased strongly by -33.27% in the last year.

The Revenue has decreased by -4.71% in the past year.

Measured over the past years, BNN shows a small growth in Revenue. The Revenue has been growing by 6.74% on average per year.

EPS 1Y (TTM)-33.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%76.38%

Revenue 1Y (TTM)-4.71%

Revenue growth 3Y12.27%

Revenue growth 5Y6.74%

Sales Q2Q%0.7%

3.2 Future

Based on estimates for the next years, BNN will show a very strong growth in Earnings Per Share. The EPS will grow by 29.29% on average per year.

The Revenue is expected to grow by 5.39% on average over the next years.

EPS Next Y31.93%

EPS Next 2Y30.79%

EPS Next 3Y25.75%

EPS Next 5Y29.29%

Revenue Next Year-0.63%

Revenue Next 2Y5.77%

Revenue Next 3Y6.99%

Revenue Next 5Y5.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNN. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BNN's earnings are expected to grow with 25.75% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.79%

EPS Next 3Y25.75%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BNN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BRAIN BIOTECH AG

FRA:BNN (12/12/2025, 7:00:00 PM)

2.97

-0.07 (-2.3%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)08-28 2025-08-28

Earnings (Next)01-14 2026-01-14/amc

Inst Owners9.19%

Inst Owner ChangeN/A

Ins Owners52.16%

Ins Owner ChangeN/A

Market Cap64.89M

Revenue(TTM)53.61M

Net Income(TTM)-13.66M

Analysts84.44

Price Target5.73 (92.93%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-25.16%

EPS NY rev (3m)-25.16%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.21
P/FCF	N/A
P/OCF	N/A
P/B	10.8
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.54

EYN/A

EPS(NY)-0.08

Fwd EYN/A

FCF(TTM)-0.31

FCFYN/A

OCF(TTM)-0.24

OCFYN/A

SpS2.45

BVpS0.28

TBVpS-0.35

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.27%
ROE	-227.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	55.6%
FCFM	N/A

ROA(3y)-10.89%

ROA(5y)-10.5%

ROE(3y)-49.48%

ROE(5y)-41.57%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.53%

GM growth 5Y-0.08%

F-Score2

Asset Turnover0.68

Health

		Industry Rank	Sector Rank
Debt/Equity	0.74
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	31.1%
Cap/Sales	2.87%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.85
Quick Ratio	1.3
Altman-Z	-0.96

F-Score2

WACC6.6%

ROIC/WACCN/A

Cap/Depr(3y)77.56%

Cap/Depr(5y)65.96%

Cap/Sales(3y)6.63%

Cap/Sales(5y)6.09%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-33.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%76.38%

EPS Next Y31.93%

EPS Next 2Y30.79%

EPS Next 3Y25.75%

EPS Next 5Y29.29%

Revenue 1Y (TTM)-4.71%

Revenue growth 3Y12.27%

Revenue growth 5Y6.74%

Sales Q2Q%0.7%

Revenue Next Year-0.63%

Revenue Next 2Y5.77%

Revenue Next 3Y6.99%

Revenue Next 5Y5.39%

EBIT growth 1Y-106.36%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year269.39%

EBIT Next 3Y86.79%

EBIT Next 5Y71.69%

FCF growth 1Y37.12%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y10.57%

OCF growth 3YN/A

OCF growth 5YN/A

BRAIN BIOTECH AG / BNN.DE FAQ

What is the fundamental rating for BNN stock?

ChartMill assigns a fundamental rating of 2 / 10 to BNN.DE.

What is the valuation status of BRAIN BIOTECH AG (BNN.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to BRAIN BIOTECH AG (BNN.DE). This can be considered as Overvalued.

Can you provide the profitability details for BRAIN BIOTECH AG?

BRAIN BIOTECH AG (BNN.DE) has a profitability rating of 1 / 10.

What is the financial health of BRAIN BIOTECH AG (BNN.DE) stock?

The financial health rating of BRAIN BIOTECH AG (BNN.DE) is 3 / 10.

BRAIN BIOTECH AG (BNN.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BRAIN BIOTECH AG / BNN.DE FAQ

What is the fundamental rating for BNN stock?

What is the valuation status of BRAIN BIOTECH AG (BNN.DE) stock?

Can you provide the profitability details for BRAIN BIOTECH AG?

What is the financial health of BRAIN BIOTECH AG (BNN.DE) stock?